Context Therapeutics (CNTX)

Context Therapeutics (CNTX) Stock Price & Analysis


CNTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.47 - $1.69
Previous Close$1.11
Average Volume (3M)41.28K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$25.10M
Total Debt (Recent Filing)$7.97K
Price to Earnings (P/E)-0.9
Nov 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding15,966,053
10 Day Avg. Volume44,690
30 Day Avg. Volume41,281
Standard Deviation0.38
Financial Highlights & Ratios
Price to Book (P/B)0.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Price Target Upside200.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.47 and its highest was $1.69 in the past 12 months.
    What is Context Therapeutics’s market cap?
    Currently, no data Available
    When is Context Therapeutics’s upcoming earnings report date?
    Context Therapeutics’s upcoming earnings report date is Nov 30, 2023 which is in 64 days.
      How were Context Therapeutics’s earnings last quarter?
      Context Therapeutics released its earnings results on Aug 09, 2023. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.115.
        Is Context Therapeutics overvalued?
        According to Wall Street analysts Context Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Context Therapeutics pay dividends?
          Context Therapeutics does not currently pay dividends.
          What is Context Therapeutics’s EPS estimate?
          Context Therapeutics’s EPS estimate is -$0.31.
            How many shares outstanding does Context Therapeutics have?
            Context Therapeutics has 15,966,053 shares outstanding.
              What happened to Context Therapeutics’s price movement after its last earnings report?
              Context Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went up 10.638%.
                Which hedge fund is a major shareholder of Context Therapeutics?
                Currently, no hedge funds are holding shares in CNTX


                Context Therapeutics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Context Therapeutics

                Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.


                Top 5 ETFs holding CNTX

                Market Value
                Smart Score
                Vanguard Total Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold CNTX. The ETFs are listed according to market value of CNTX within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                vTv Therapeutics
                Molecular Templates

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis